semaglutide and tumors (Ozempic) carries FDA warnings for thyroid C-cell based on rodent studies, with emerging human data showing higher thyroid cancer risk in early users. Over 2,900 lawsuits allege inadequate warnings for FDA Approves Oral Semaglutide as
Description
Clinical trials show appetite hormones (GLP-1, PYY, GIP) return toward baseline within weeks of stopping medication, increasing hunger signals and food cravings significantly
The downside to GLP-1 drugs is that all but one has to be taken by a shot
A., Oleson, B
Others are regulatory and legal maneuvers that extend exclusivity without material therapeutic value
[PubMed] [Google Scholar] 818.Krass M., Volke A., Runkorg K., Wegener G., Lund S., Abildgaard A
Saxenda, being an older GLP-1 medication, has some downsides compared to newer GLP-1 medications
